Table 3. Percentage of patients with pneumonia in recent studies investigating ICS/LABA combinations versus LABA monotherapy in COPD patients.
| Study reference | Drugs and total daily dose (μg) | Study duration |
% of patients with pneumonia
|
|
|---|---|---|---|---|
| ICS/LABA | LABA | |||
| Calverley et al. 12 | FP/S 1000/100 versus S 100 | 3 years | 19.6 | 13.3 |
| Kardos et al. 45 | FP/S 1000/100 versus S 100 | 44 weeks | 4.5 | 1.4 |
| Calverley et al. 3 | BUD/FF 640/18 versus FF 18 | 12 months | 3.1 | 2.7 |
| Ferguson et al. 4 | FP/S 500/100 versus S 100 | 12 months | 7.0 | 4.0 |
| Rennard et al. 7 | BUD/FF 320/9 versus FF 9 | 12 months | 3.0 | 3.4 |
| Rennard et al. 7 | BUD/FF 160/9 versus FF 9 | 12 months | 3.0 | 3.4 |
| Anzueto et al. 46 | FP/S 500/100 versus S 100 | 52 weeks | 6.6 | 2.5 |
| Carlverley et al. 20 | BDP/FF 400/24 versus FF 24 | 48 weeks | 2.1 | 0.4 |
| Carlverley et al. 20 | BUD/FF 800/24 versus FF 24 | 48 weeks | 2.9 | 0.4 |
| Sharafkhaneh et al. 44 | BUD/FF 320/9 versus FF 9 | 12 months | 6.4 | 2.7 |
| Sharafkhaneh et al. 44 | BUD/FF 160/9 versus FF 9 | 12 months | 4.7 | 2.7 |
| Dransfield et al. 6 | FF/Vil 100/25 versus Vil 25 | 52 weeks | 6.3 | 3.3 |
| Wedzicha et al. 28 | BDP/FF 400/24 versus FF 24 | 48 weeks | 3.8 | 1.8 |
Studies >6 months duration were included.
Abbreviations: COPD, chronic obstructive pulmonary disease; ICS/LABA, inhaled corticosteroid/long-acting β2-agonist.